CellCarta
Carol Berry currently serves as the Chief Business Officer at Cx Precision Medicine, Inc. and is a Board Member at both InterVenn Biosciences and iNDX.Ai. Prior to these roles, Carol was the Chief Business Officer and Senior Vice President at CellCarta, which specializes in precision medicine laboratory services, from January 2014 to January 2023. Carol also held the position of Senior Vice President and General Manager of the Pharmacogenomic Services Division at Asuragen from May 2008 to December 2013 and was the Global Head of Sales and Marketing at Ciphergen Biosystems, Inc. from 2002 to 2008. Carol Berry earned an MBA in Information Technology and Science from Texas A&M University between 2000 and 2004.
This person is not in any offices
CellCarta
CellCarta's Mission is centered on collaborating and partnering with pharmaceutical and biotech companies through proteomics and immune monitoring enabling the acceleration of precision medicine in drug development.With a vision and deep understanding of the needs for complex immune monitoring in novel drug development, Caprion integratedImmuneCarta (formerly known as National Immune Monitoring), with its established and proven proteomics service, ProteoCarta. Together, Caprion now offers a fully integrated and unique service offering to its partners.